FibroBiologicsFBLG
FBLG
About: FibroBiologics Inc is a clinical-stage cell therapy company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with unmet medical needs, including degenerative disc disease, multiple sclerosis, wound healing, and certain cancers, and potential extension of life applications including thymic and splenic involution reversal.
Employees: 13
0
Funds holding %
of 7,407 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
140% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 10
100% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 4
3% more funds holding
Funds holding: 61 [Q3] → 63 (+2) [Q4]
1.61% more ownership
Funds ownership: 15.53% [Q3] → 17.14% (+1.61%) [Q4]
29% less capital invested
Capital invested by funds: $16.8M [Q3] → $11.9M (-$4.91M) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$12
908%
upside
Avg. target
$14
1,076%
upside
High target
$16
1,245%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
D. Boral Capital Jason Kolbert 21% 1-year accuracy 74 / 353 met price target | 1,245%upside $16 | Buy Maintained | 9 Apr 2025 |
HC Wainwright & Co. Matthew Caufield 24% 1-year accuracy 16 / 68 met price target | 908%upside $12 | Buy Reiterated | 1 Apr 2025 |
Financial journalist opinion
Based on 6 articles about FBLG published over the past 30 days
Neutral
GlobeNewsWire
1 week ago
FibroBiologics to Present at The Cell & Gene Meeting on the Mediterranean
HOUSTON, April 11, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending for the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Hamid Khoja, Ph.D., Chief Scientific Officer of FibroBiologics, will present on FibroBiologics' unique fibroblast cell-based approach for the potential treatment of chronic diseases at The Cell & Gene Meeting On The Mediterranean (Med) in Rome, Italy, from April 15-17, 2025. The Cell & Gene Meeting on the Med is the leading conference bringing together the Advanced Therapy Medicinal Products community from Europe and beyond.
Neutral
GlobeNewsWire
1 week ago
FibroBiologics Unveils New and Expanded Houston Laboratory Space to Pursue Innovation and Breakthroughs in Fibroblast-Based Therapeutics
Located in Houston, Texas, the new facility allows FibroBiologics to expand its research and development efforts utilizing fibroblast-based technology Located in Houston, Texas, the new facility allows FibroBiologics to expand its research and development efforts utilizing fibroblast-based technology
Neutral
GlobeNewsWire
2 weeks ago
FibroBiologics Announces Scientific Advancement in Confirmation Results of Brain Tissue Repair
HOUSTON, April 02, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending for the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced a significant advancement in neurodegenerative disease research. Leveraging the well-established Cuprizone animal model, FibroBiologics has demonstrated that intravenous fibroblasts can facilitate remyelination.
Neutral
GlobeNewsWire
2 weeks ago
FibroBiologics Reports Full Year 2024 Financial Results and Provides Corporate Update
Proprietary master cell bank of fibroblast-based spheroids product candidate, CYWC628, completed in accordance with Good Manufacturing Practices after successfully passing all required safety testing
Neutral
GlobeNewsWire
3 weeks ago
FibroBiologics Announces 2025 Annual Meeting of Stockholders
HOUSTON, March 27, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that its 2025 Annual Meeting of Stockholders will take place on June 12, 2025, at 11 a.m. CDT, exclusively through a virtual format. The record date for determination of stockholders entitled to vote at the annual meeting is April 14, 2025.
Neutral
GlobeNewsWire
4 weeks ago
FibroBiologics to Present at The German-Nordic Joint Extracellular Matrix Meeting
HOUSTON, March 21, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Hamid Khoja, Ph.D., Chief Scientific Officer of FibroBiologics, will present on FibroBiologics' unique fibroblast cell-based approach for the potential treatment of chronic diseases at The German-Nordic Joint Extracellular Matrix Meeting in Freiburg, Germany, from March 26-28, 2025. The joint meeting is an annual opportunity to showcase advances in extracellular matrix biology.
Neutral
GlobeNewsWire
1 month ago
FibroBiologics Files Patent For Novel Approach to Modulate Mitochondrial Activity Using Fibroblast-based Therapeutics
This innovative method has the potential to unlock new treatment options for chronic conditions driven by mitochondrial dysregulation.
Neutral
GlobeNewsWire
1 month ago
FibroBiologics and Charles River Announce Completion and Release of CYWC628 Master Cell Bank for the Manufacturing of Fibroblast Cell-based Wound Healing Therapeutic
Master cell bank to be used in manufacturing of CYWC628 drug product to support upcoming clinical trial for diabetic foot ulcers Master cell bank to be used in manufacturing of CYWC628 drug product to support upcoming clinical trial for diabetic foot ulcers
Neutral
GlobeNewsWire
2 months ago
FibroBiologics to Host In-Person Analyst Day to Provide Research & Development Updates
HOUSTON, Feb. 05, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced that it will host an in-person analyst day at the New York Marriott Marquis on February 12, 2025, at 2:00 p.m. ET. The event will feature presentations from the following members of the Company's management: Pete O'Heeron, Chief Executive Officer Hamid Khoja, PhD, Chief Scientific Officer Robert Hoffman, Interim Chief Financial Officer The event will highlight FibroBiologics' research and development strategy for advancing fibroblast-based therapeutics to address chronic diseases.
Neutral
GlobeNewsWire
3 months ago
FibroBiologics Closes Second $5 Million Tranche of $25 Million Financing
HOUSTON, Dec. 30, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced that it has closed the second $5 million tranche of the previously announced Standby Equity Purchase Agreement (the “SEPA”) with YA II PN, LTD. (“Yorkville”), an investment fund managed by Yorkville Advisors Global, LP. The agreement allows FibroBiologics, subject to customary conditions, to sell up to $25 million in the aggregate of its common stock to Yorkville over the course of two years.
Charts implemented using Lightweight Charts™